Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

@article{Hart2007MetaanalysisAT,
  title={Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation},
  author={Robert G. Hart and Lesly A. Pearce and Maria I. Aguilar},
  journal={Annals of Internal Medicine},
  year={2007},
  volume={146},
  pages={857-867}
}
Context Thirteen new randomized, controlled trials are available since a 1999 meta-analysis of antithrombotic agents for stroke prevention in patients with atrial fibrillation. Contribution This updated meta-analysis shows that, compared with placebo, adjusted-dose warfarin reduces stroke risk by 64% (6 trials) and antiplatelet agents reduce stroke risk by 22% (8 trials). Meta-analysis of 12 trials shows that adjusted-dose warfarin is more effective than antiplatelet therapy, but it doubles the… 
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
TLDR
Current use of warfarin as a stroke prevention agent in patients with AF is associated with a low rate of residual stroke or systemic embolism, compared with a previous meta-analysis, and there has been significant improvement in the proportion of time spent in therapeutic anticoagulation.
Review of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial: Warfarin Versus Dabigatran
TLDR
Factor such as drug and dietary interactions, delayed onset and offset of action, cumbersome International Normalized Ratio (INR) monitoring, elevated risk of bleeding, and difficulties maintaining a therapeutic INR all contribute to limiting the number of patients prescribed warfarin, as well as decreasing the time in the therapeutic window for patients on warfar in therapy.
Stroke prevention in atrial fibrillation: do we still need warfarin?
TLDR
New anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer a number of advantages over warfarin, for both the clinician and patient, including a favourable bleeding profile and convenience of use.
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
TLDR
Dabigatran is shown to be especially cost-effective for high stroke-risk patients, those with a CHADS2 score of > 3 (barring excellent INR control) and for lower- risk patients with aCHADS2 of 2 but concomitant high risk of hemorrhage, and may exhibit the same cost savings as factor Xa inhibitors, such as rivaroxaban and apixaban.
Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score
Atrial fibrillation (AF) is an expanding epidemic,1 and ischaemic stroke due to cardioembolism remains a trademark serious complication of AF.2 The now historical stroke prevention in AF trials
Prevention of Stroke in Patients with Atrial Fibrillation: The Role of New Antiarrhythmic and Antithrombotic Drugs
TLDR
Novel antithrombotic agents and antiarrhythmic agents with cardiovascular prophylactic properties may enhance the management of stroke risk in patients with AF.
Atrial fibrillation and mortality: the impact of antithrombotic therapy.
TLDR
The largest trial to date, the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W) trial, revealed a 37% reduction in all strokes associated with dose-adjusted warfarin but did not demonstrate a significant mortality benefit ofwarfarin over aspirin.
Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis
TLDR
The present meta-analysis suggests that TOAT (aspirin + clopidogrel + warfarin) therapy for patients with AF concurrent to PCIS significantly reduced the risk of MACE and stroke compared with DAPT (aspirationin +ClopidOGrel) therapy.
Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review.
Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients
TLDR
In this network meta-analysis, novel oral anticoagulants were the most promising treatments to reduce stroke, stroke or systemic embolism, and all-cause mortality in patients with AF.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
TLDR
Considering all randomized data, aspirin modestly reduces stroke and major vascular events in nonvalvular AF, and reductions in these events by aspirin were consistently smaller and marginally statistically significant.
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
TLDR
For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe, and further prospective studies are needed to determine the best preventive therapy for cerebrovascular events in Japanese patients withNVAF.
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
TLDR
The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation.
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).
TLDR
D dose-adjusted warfarin was significantly better tolerated with fewer adverse events than aspirin 300 mg in this elderly population and there was no evidence for efficacy in AF at this dose.
[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].
TLDR
It is demonstrated that anticoagulation with adjusted-dosed warfarin (INR 2.0 - 3.0) can significantly reduced the risk of thromboembolism event with slightly increased hemorrhage, compared to aspirin in Chinese population.
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
TLDR
Low-intensity anticoagulation with warfarin prevented cerebral infarction in patients with nonrheumatic atrial fibrillation without producing an excess risk of major hemorrhage, and this benefit extended to patients over 70 years of age.
Stroke Prevention in Atrial Fibrillation Study: Final Results
TLDR
Aspirin and warfarin are both effective in reducing ischemic stroke and systemic embolism in patients with atrial fibrillation and patients with nonrheumatic atrialfibrillation who can safely take either aspirin or warfarIn should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
Antithrombotic therapy for stroke prevention in atrial fibrillation.
...
1
2
3
4
5
...